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Objective: To estimate first-year costs among new initiators of topical prostaglandin analogs 
in a managed care population.
Research design and methods: We developed a model to estimate first-year direct medical 
costs. We derived treatment patterns from a claims database analysis. Published studies were 
used to estimate visit-related resource use. Costs were obtained from standard sources.
Results: The database analysis identified 9,063 patients meeting study criteria, 41% (n = 3,672) 
of whom remained on their initial prostaglandin therapy for 12 months after initiation. Adjunctive 
intraocular pressure lowering therapy was needed in 20.7%, 16.5%, 13.9%, and 8.9% of 
bimatoprost, latanoprost, travoprost, and BAK-free travoprost patients, respectively. Median 
numbers of days to the first prescription filled for adjunctive therapy (if required) were 69.5, 67.0, 
123.0, and 158.5 for patients initiating on bimatoprost, latanoprost, travoprost, and BAK-free 
travoprost. Total estimated first-year costs were $1,457, $1,360, $1,278, and $1,307 for patients 
initiating therapy with bimatoprost, latanoprost, travoprost, and BAK-free travoprost. Findings 
were consistent through sensitivity analysis.
Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy 
and be associated with lower first-year direct medical costs. Use of a claims database and the 
selection of new initiators of prostaglandin analogs limit projecting findings to all glaucoma 
patients.
Keywords: costs and cost analysis, drug therapy, combination, glaucoma, prostaglandin analogs
Patient adherence to glaucoma treatment regimens is essential to maintain maximum 
intraocular pressure (IOP) reduction and slow disease progression in patients 
with primary open-angle glaucoma (POAG). This IOP reduction however, may be 
difficult to achieve.1 A number of factors may influence a patient’s adherence to 
therapy, including experience with adverse events associated with treatment and 
understanding of the disease and the risk of reduced vision.2 Additionally, persistence 
rates vary across classes of glaucoma medications, with prostaglandin analogs 
associated with significantly higher persistence than other medications.1,3 Even 
though prostaglandin analogs are widely used as initial therapy, monotherapy cannot 
always sufficiently lower IOP.4–6 Adjunctive therapies, such as topical ophthalmic 
beta-blockers, alpha-2 agonists, and carbonic anhydrase inhibitors are quite often 
required to increase IOP control. The use of adjunctive treatments may result in 
more complicated dosing regimens, an increase in adverse events, and a greater 
likelihood of poor patient adherence,7 which could lead to disease progression. Clinical Ophthalmology 2009:3 638
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Also, a recent study suggests that there are diminishing 
returns to adding a third and fourth therapy to a glau-
coma treatment regimen.8 With the implications of poor 
adherence, the development of medications that minimize 
barriers to adherence can have an important impact on the 
success and costs of treatment.
A series of studies exploring the impact of adjunctive 
therapies on direct medical costs appears to demonstrate 
an economic benefit to extended monotherapy treatment. 
The first study compared treatment patterns and estimated 
annual costs of patients newly initiating therapy with one 
of three prostaglandin analogs: bimatoprost, latanoprost, or 
travoprost.9 Findings suggest that the timing of introducing 
adjunctive therapy is a key determinant of annual costs. 
A second, later study using the same methods compared 
all prostaglandin analogs approved by the US Food and 
Drug Administration, which included a new formulation 
of travoprost.10 This newer product, BAK-free travoprost, is 
comparable in concentration to the conventional travoprost 
using BAK and may be beneficial to those with ocular sur-
face disease (OSD) or sensitivity to BAK.11 Both preclinical 
and clinical studies have demonstrated BAK’s toxicity to 
the ocular surface.12–14 More than half of glaucoma patients 
experience some signs and/or symptoms of OSD in at least 
one eye.15 Comparisons of the original and reformulated 
versions of travoprost show that the two drugs are similar 
in terms of efficacy but that BAK-free travoprost produces 
improved tolerability.13,16,17 Use of preservatives with less 
toxicity may maintain vision-related quality of life and be 
associated both with better patient acceptance, increased 
persistence, and with less ophthalmologist follow-up care.11 
The present study is the first in which it was anticipated 
that there would be a sufficient number of patients using 
BAK-free travoprost to examine their treatment patterns 
separately.
The goals of this study were to evaluate the treatment 
patterns and annual costs of patients newly initiating therapy 
with prostaglandin analogs as first-line therapy and to explore 
the effects of a BAK-free prostaglandin analog formulation 
on treatment patterns and direct medical costs.
Methods
We used three primary sources of input into the economic 
model. We first conducted a retrospective cohort study using 
a prescription benefits database. Data from this analysis were 
used to identify the population of patients receiving prosta-
glandin analogs and to explore patterns of use of adjunctive 
therapies. Second, we reviewed published studies identified 
through a literature review to estimate the components of 
a typical outpatient visit (initial evaluation and diagnostics 
tests and follow-up care). Finally, we consulted standard cost 
sources to provide costs for each resource (initial treatments, 
adjunctive therapies, visits) identified.
Database analysis: study population 
and use of adjunctive therapies
The patients described in the retrospective cohort analysis 
were receiving prescription benefits and were included in 
a prescription claims database of a large pharmaceutical 
benefits manager (PBM). This PBM serves more than 
75 million plan participants across the United States. 
All data were de-identified in accordance with Protected 
Health Information standards under the Health Informa-
tion Portability and Accountability Act 1996 so that no 
individually identifiable information was included in the 
study database. Therefore, review by an institutional review 
board was not required.
The study cohort included patients who first initiated 
therapy with one of four prostaglandin analog products 
(bimatoprost, latanoprost, travoprost, or BAK-free travo-
prost) between May 1st, 2007 and October 31st, 2007. 
To qualify, patients had to have more than one prostaglandin 
analog prescription claim and six months of prior claims 
data in which there were no glaucoma therapy claims. 
Glaucoma therapy claims were defined by therapeutic 
class plus generic code number (GCN) codes. GCNs are a 
system of unique numbers assigned to medications accord-
ing to strength, formulation, route of administration, and 
size by drug pricing service First DataBank. The study 
population was further defined by requiring patients to 
have at least 12 months of uninterrupted use of the index 
prostaglandin analog following the initial prescription. This 
was operationalized as not having prescriptions for the other 
prostaglandin analogs during the year and having at least 
one prescription for the index prostaglandin analog in the 
fourth quarter of the follow-up period. Patients who did 
not meet these requirements (sufficient prior claims data, 
uninterrupted use, and use of the index prostaglandin analog 
during the fourth quarter of observation) were excluded 
from the study database. Patients who switched from one 
formulation of travoprost to the other were also excluded 
from the analysis.
We considered that patients added an adjunctive medica-
tion, defined by therapeutic class plus GCN codes, if there 
was a sequential and subsequent refill of an adjunctive agent 
in the presence of continued refills for the index agent.Clinical Ophthalmology 2009:3 639
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Literature review: resource use 
and cost inputs
The American Academy of Ophthalmology Preferred 
Practice Patterns for glaucoma suggest that follow-up care 
should be based on achievement of target IOP and the amount 
of disease progression,18 neither of which was available in the 
prescription database used for this study. Therefore, the base 
case analysis used resource rates from a survey-based study19 
while sensitivity analyses explored visits as recommended 
by other studies and guidelines.18,20 Since all patients in the 
model are assumed to have undergone the same procedures 
and tests at their visits regardless of the prostaglandin analog 
they received, the relatively small differences across studies 
in terms of the components of each visit have minimal impact 
on study findings.
At the initial visit, patients were assumed to have a level 4 
(comprehensive) evaluation (CPT 92004). Follow-up visits 
were assumed to be level 2 (intermediate) visits (CPT 92012), 
with three follow-up visits during the year (likely but not 
necessarily at 30 and 90 days following initiation of the 
index therapy and at 12 months). In addition, two follow-up 
visits were assumed to be associated with the initiation and 
monitoring of adjunctive medication among patients for 
whom it was prescribed. Table 1 presents the procedures 
and diagnostic tests that comprised each visit as well as the 
costs used for each.
We use average wholesale price (AWP) for 2008 as 
the prescription costs.21 The range of published AWPs for 
the prostaglandin analogs was fairly narrow (US$72.20 to 
$76.69).21 For the prostaglandin analogs, the average cost 
for the agents was used in the model because AWP does not 
take into consideration contract pricing and rebates, which 
minimize, if not eliminate, differences in cost to the insurer. 
Further, the number of prescriptions for prostaglandin 
analogs was normalized to a 2.5 mL bottle, as this was the 
most common size found in the claims database. Medical 
costs were estimated using the 2008 Medicare Fee Schedule.22 
All the costs used in the model are presented in Table 1.
Days of use per bottle were based on data from this 
population. Number of bottles required was rounded to the 
nearest tenth.
Analysis
The analysis identified patients by the prostaglandin whose 
prescription they first filled during the study period. Statistical 
comparisons of the demographic characteristics of the four 
cohorts were conducted in SAS software (v9.2; SAS Institute, 
Cary, NC). Gender was compared using a Chi-squared test 
and age was compared using analysis of variance (ANOVA), 
with Bonferroni’s correction for multiple comparisons. 
Median and mean number of days to initiation of adjunctive 
therapy were calculated for each cohort, with the distribution 
of number of days examined to determine which measure 
to use in the model. The median numbers of days until 
patients added adjunctive therapies were compared using 
the Wilcoxon rank sum test and mean times were compared 
using ANOVA.
Sensitivity analyses explored potential changes in clinical 
and cost parameters. These scenarios are detailed in Table 5. 
First, the proportion of patients remaining on monotherapy 
Table 1 Unit costs
Resource Description/Size Cost
initial visit CPT 92004 (comprehensive, new patient) plus 
weighted costs for visual field exam (92082), 
gonioscopy (92020), evaluation of optic disc (92135), 
optic nerve head photograph (92235), and fundus 
evaluation (92250) per Fremont and colleagues19
$395.7014
Follow-up visit CPT 92012 (intermediate, established patient), visual 
acuity exam (99173) per Fremont and colleagues19
$72.8714
Prostaglandin analog 2.5 ml $75.0713
Fixed combination dorzolamide 
2.0%/timolol 0.5%
5 ml $67.4113
Brimonidine 0.1% 5 ml $54.3413
Dorzolamide 2% 10 ml $67.4113
Timolol 0.25% 5 ml $17.9313
Other 5 ml $52.37 (assumption)Clinical Ophthalmology 2009:3 640
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for the entire year was changed to the lowest and highest 
values among the initial treatments, that is, the proportion of 
patients remaining on monotherapy was changed to 79.3% 
(the base case value for bimatoprost) and then to 91.1% (the 
base case value for BAK-free travoprost) for all treatments. 
Second, the days to initiating adjunctive therapy was varied 
in two ways: a) median number of days to the addition of 
adjunctive medication was changed to the lowest and highest 
values among the treatments and b) the mean number of days 
was substituted for the median. Third, the cost of treatments 
were varied by a) assuming that the least and most expen-
sive adjunctive therapies were the only therapies used and 
b) rounding up bottles of index and adjunctive therapies to 
whole numbers. Fourth, sensitivity analysis was conducted 
on the cost of visits, using resource use estimates from 
other published sources.18,20 The preferred practice patterns 
published by the American Academy of Ophthalmology 
were used to establish minimum and maximum values for 
the frequency of visits and resource visits. The minimum 
values assumed that patients were meeting IOP targets and 
the maximum values assumed that patients were not meeting 
IOP targets and that there was progression of disease.
Results
Figure 1 provides a brief flow chart of the patient selection 
process for the retrospective cohort analysis. Of more than 
75 million plan participants, 9,063 initiated treatment with 
a prostaglandin analog. Approximately 6% of these patients 
switched from their index prostaglandin analog within the 
12-month study period to another glaucoma therapy. This 
ranged narrowly among the study cohorts from 5.0% to 
8.6%. Additionally, about 54% of the patients stopped taking 
all glaucoma medications within the 12-month period. This 
also ranged narrowly among the cohorts from 51.3% to 
58.2%. The analysis examined only those newly initiating 
patients who remained on their initial prostaglandin analog 
therapy for one year, which represents approximately 41% 
of the glaucoma patients newly initiating with prostaglandin 
analogs identified from the database.
Demographic characteristics of the 9,063 newly initiating 
patients are presented in Table 2. More than half of the 
patients were women. The mean age across groups ranged 
from 64 to 65 years. There were no statistically significant 
differences among groups in terms of age or gender.
In the bimatoprost, latanoprost, travoprost, and 
BAK-free travoprost treatment groups, 20.7%, 16.5%, 
13.9%, and 8.9%, respectively, initiated adjunctive therapy 
during the course of the year at significantly different pro-
portions (P  0.0001, see Table 3). Patients on BAK-free 
travoprost were able to continue without adjunctive therapy 
longer than patients treated with other prostaglandins. The 
median numbers of days until patients added adjunctive 
therapies were 158.5 days for patients initiating therapy 
with BAK-free travoprost, 123.0 days for travoprost, 
69.5 days for bimatoprost, and 67.0 days for latanoprost 
(P  0.05, Wilcoxon rank sum test). The mean numbers of 
days to initiating adjunctive therapy were 156.3 days in the 
BAK-free travoprost group and 131.5 days in the travoprost 
group. For bimatoprost and latanoprost, the mean number 
of days was 120.8 and 108.3, respectively. Mean time to 
initiating adjunctive therapy was not significantly different 
across the cohorts.
As shown in Table 4, patients had an average of 8.0 to 
9.7 prescription claims (normalized to 2.5 ml bottles) for 
Participants who had
12 months of uninterrupted
use of index prostaglandin
N = 3,672
Participants who
switched to another
prostaglandin
N = 529
Participants who
stopped using all
glaucoma medications
N = 4,862
Participants with no previous
 glaucoma medications prior to
starting on a prostaglandin analog
N = 9,063
Plan participants
N = 75,000,000
Figure 1 Patient selection.Clinical Ophthalmology 2009:3 641
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prostaglandin analog therapy during the 12-month follow-up 
period. Based on the time to initiating adjunctive therapy, 
anywhere from 4.6 to 10.5 bottles of adjunctive medication 
were required for the remainder of the year. Reflective of the 
shorter time to initiation of adjunctive therapy, the number 
of prescriptions for adjunctive therapies was highest for 
latanoprost, while fewer bottles were required for BAK-free 
travoprost patients, who began adjunctive therapy later.
All the costs used in the model are presented in Table 1. 
Figure 2 presents the primary findings from the analysis. 
Estimated annual costs for patients initiating travoprost 
were lowest ($1,278), with increasing annual costs for 
BAK-free travoprost ($1,307), latanoprost ($1,359), and 
bimatoprost ($1,457). The cost of travoprost was lower 
than BAK-free travoprost primarily due to slightly fewer 
2.5 ml equivalent bottles being used on average during the 
year (8.0 vs 8.7).
Results of sensitivity analyses are shown in Table 5. 
Findings remained consistent, with travoprost having the 
lowest annual cost and bimatoprost having the highest cost 
in all scenarios. The range narrowed (to less than $100) when 
the number of bottles of index prostaglandin was equalized 
across cohorts or when the cost for visits was based on guide-
lines and widened (to more than $200) when the number of 
bottles of index prostaglandin was rounded up to the nearest 
whole number.
Discussion
This analysis adds to a growing body of literature finding 
consistent differences in treatment patterns and costs for 
glaucoma patients initiating treatment with prostaglandin 
analogs with varying rates of use of adjunctive therapy. 
The cohort analysis found that patients receiving BAK-free 
travoprost remained on monotherapy in greater proportions 
and for a longer duration compared to other prostaglandin 
analogs.
Compared to the previous studies in this series,9,10 a number 
of findings should be highlighted. First, the high rate of 
monotherapy adherence in the initial study in the series9 
seems to have been an aberration, with both the second10 
and present studies finding more than half of the patients 
identified as discontinuing glaucoma therapies within one 
year, in agreement with other published studies.3,23–25 Second, 
the advantage travoprost demonstrated in terms of less 
use of adjunctive therapies associated with new patients 
starting on this therapy was consistent across studies, and 
the introduction of the BAK-free formulation only increased 
this advantage. A possible explanation for longer duration 
Table 2 Demographic characteristics
Characteristic BAK-free travoprost Travoprost Bimatoprost Latanoprost
n 1,150 1,046 1,792 5,075
Age, mean ± standard deviation 63.6 ± 13.5 64.6 ± 13.9 64.5 ± 14.1 63.8 ± 14.7
gender, % female 57.4% 54.1% 54.2% 55.9%
Table 3 Treatment patterns during follow-up period
Treatment pattern Index therapy
BAK-free travoprost Travoprost Bimatoprost Latanoprost
number on index therapy (n) 404 316 735 2217
Remained on monotherapy (%)* 91.1% 86.1% 79.3% 83.5%
Required adjunctive therapy (%) 8.9% 13.9% 20.7% 16.5%
  Median time to adding adjunctive therapy (days)** 158.5 123.0 69.5 67.0
  Mean time to adding adjunctive therapy (days) 156.3 131.5 120.8 108.3
Type of adjunctive therapy:
  α2-adrenergic receptor agonist (%) 30.5% 15.9% 22.4% 26.8%
  Beta-blocker (%) 27.8% 38.6% 28.9% 35.6%
  Carbonic anhydrase inhibitor (%) 16.7% 25.0% 17.1% 12.6%
  Fixed-combination beta-blocker/carbonic anhydrase inhibitor (%) 16.7% 15.9% 25.7% 18.9%
  Other adjunctive therapy (%) 8.3% 4.6% 5.9% 6.1%
Notes: *P  0.0001, chi-squared test; **P  0.05,   Wilcoxon rank sum test.Clinical Ophthalmology 2009:3 642
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of monotherapy and fewer patients requiring adjunctive 
therapy is greater patient adherence due to lower rates of 
OSD associated with BAK-free travoprost.13,16,17
The use of pharmacy claims databases alone to estimate 
adherence poses methodological challenges24 and is fur-
ther complicated by the fact that assuming appropriate 
refill patterns do not imply appropriate instillation of eye 
drops.26–31 Regardless of the reason, BAK-free travoprost 
has been shown to be at least as safe and efficacious as 
travoprost13,17 and if it can also improve adherence by being 
a more eye-friendly drug, then real-world effectiveness 
might be enhanced. While the safety of the BAK-free 
preservative has been widely demonstrated, various reports 
have identified cystoid macular edema after treatment with 
prostaglandin analogs.32–35 BAK-free travoprost is associated 
with less OSD, but high-risk patients must still be monitored 
for other adverse events, as with any of the medications in 
the class.
There are some notable study limitations. The patients 
in this analysis, while generally reflective of the larger 
glaucoma patient population in terms of demographic char-
acteristics,36 may not reflect the larger population in other 
facets. The study attempted to identify only patients who 
were new to therapy, although even a criterion as simple 
as this is difficult to implement.24 These patients had pre-
scription coverage, and since finances are one reason cited 
for nonadherence with glaucoma therapy,2 this may be an 
important difference. Also, based on the study methodol-
ogy, patients may have had poor adherence; patients in 
the cohort analysis were required to have a minimum of 
two glaucoma prescriptions filled during the follow-up 
period, but no attempt was made to assess medication 
Table 4 Resource use during follow-up period
Treatment pattern Index therapy
  BAK-free travoprost Travoprost Bimatoprost Latanoprost
Mean number of prostaglandin analog  
prescriptions (normalized to 2.5 ml)
8.7 8.0 9.7 8.7
Mean number of prescriptions for other glaucoma  
medications
  α2-adrenergic receptor agonist (brimonidine 0.1%) 7.2 8.5 10.4 10.5
  Beta-blocker (timolol 0.25%) 5.2 6.1 7.4 7.5
  Fixed combination (dorzolamide 2.0%/timolol 0.5%) 5.7 6.7 8.2 8.3
  Carbonic anhydrase inhibitor (dorzolamide 2%) 4.6 5.4 6.6 6.7
  Other 6.4 7.5 9.2 9.3
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possession ratio or to evaluate persistence with therapy 
over time. As shown in multiple other studies, more than 
half of the patients identified in studies of glaucoma therapy 
discontinue.10,23–25,37 The subset of patients identified through 
this analysis may not be representative of glaucoma patients 
in other aspects.
The use of a large claims database offers an important 
strength in terms of sample size. However, there are also 
disadvantages to the use of a pharmaceutical claims database 
without additional clinical input. Patients are not randomly-
assigned to treatment and although sample size should help 
minimize any bias, it is possible that there are systematic 
preferences for treatments that cannot be detected without 
additional clinical information. The reasons for adding 
adjunctive therapy or switching or discontinuing therapies 
cannot be surmised from the claims database alone. Knowing 
more about these reasons might inform the study question 
however, it is impossible to know these answers. In addi-
tion, claims databases report on prescriptions filled, but 
cannot be used as a definitive statement of adherence.26,28–30 
This is further complicated with the study of eye drops, 
where effective instillation of drops is a problem even 
among patients who try to adhere to therapy.27,31 The patient 
population in any given database may not match the overall 
population of patients with the condition in question nor were 
patients randomized to treatment, although age and gender 
distributions here were similar across treatment groups and 
seem comparable with the glaucoma population. Finally, 
claims databases also may contain coding biases or errors, 
although there is no reason to believe that these errors would 
be different across index treatments also.
Adjunctive therapies were found to be a relatively small 
contributor to costs in this analysis; however, it is one of the 
few areas in which products can be differentiated. These 
findings showed that prostaglandin analogs with a greater 
proportion of patients remaining on monotherapy and a 
longer time to initiation of adjunctive agents had lower 
first-year direct medical costs from a third party payer’s 
perspective. Accordingly, costs from the patient’s perspective 
(eg, co-pay for visits and prescriptions) would also be lower 
with longer duration of monotherapy. Further study is needed 
to identify to what extent tolerability, specifically the absence 
of BAK, contributes to use of adjunctive medications among 
glaucoma patients.
Disclosure
JKS is an employee of Exponent, which received funding 
from Alcon to conduct this study. DWC is an employee of 
Alcon Research Ltd. ALR is a consultant for Alcon Labora-
tories and Alcon Research Ltd.
Table 5 Sensitivity analyses during the follow-up period
Parameter changed  
Value to which it was changed
BAK-free travoprost  Travoprost  Bimatoprost  Latanoprost 
Base case $1,307 $1,278 $1,457 $1,359
Patients on monotherapy (%)
  Decreased to 79.3% for all $1,359 $1,309 $1,457* $1,383
  increased to 91.1% for all $1,307* $1,255 $1,392 $1,317
Days to adjunctive therapy
  Mean days to adjunctive therapy $1,307* $1,277 $1,442 $1,350
  Decreased to 67.0 days for all $1,318 $1,288 $1,457 $1,359*
  increased to 158.5 days for all $1,307 $1,272 $1,431 $1,339
Cost of therapies
  Changed to least expensive adjunctive (beta-blocker) $1,290 $1,252 $1,403 $1,317
  Changed to most expensive adjunctive (fixed combination) $1,317 $1,299 $1,490 $1,391
  Rounded up index therapy bottles $1,329 $1,278* $1,479 $1,382
  Same number of index bottles across cohorts (9.0) $1,329 $1,353 $1,404 $1,382
  Rounded up adjunctive bottles $1,309 $1,281 $1,463 $1,364
Cost of visits – alternative practice patterns
  Based on Quigley and colleagues20 $1,187 $1,158 $1,337 $1,239
  Based on American Academy of Ophthalmology
    Minimum $1,441 $1,413 $1,591 $1,494
    Maximum18 $2,647 $2,619 $2,797 $2,700
Note: *no change from base case.Clinical Ophthalmology 2009:3
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